NO852603L - Apparatur og fremgangsmaate for pulsert administrering av vekstaktiverende midler. - Google Patents

Apparatur og fremgangsmaate for pulsert administrering av vekstaktiverende midler.

Info

Publication number
NO852603L
NO852603L NO852603A NO852603A NO852603L NO 852603 L NO852603 L NO 852603L NO 852603 A NO852603 A NO 852603A NO 852603 A NO852603 A NO 852603A NO 852603 L NO852603 L NO 852603L
Authority
NO
Norway
Prior art keywords
grf
administration
approx
dosage
dynamic
Prior art date
Application number
NO852603A
Other languages
English (en)
Norwegian (no)
Inventor
Daniel M Linkie
Michael O Thorner
Original Assignee
Daniel M Linkie
Michael O Thorner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daniel M Linkie, Michael O Thorner filed Critical Daniel M Linkie
Publication of NO852603L publication Critical patent/NO852603L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
    • A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
    • A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Fodder In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO852603A 1984-06-29 1985-06-28 Apparatur og fremgangsmaate for pulsert administrering av vekstaktiverende midler. NO852603L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/626,400 US4747825A (en) 1984-06-29 1984-06-29 Apparatus and methodology for pulsed administration of growth promoting agents

Publications (1)

Publication Number Publication Date
NO852603L true NO852603L (no) 1985-12-30

Family

ID=24510242

Family Applications (1)

Application Number Title Priority Date Filing Date
NO852603A NO852603L (no) 1984-06-29 1985-06-28 Apparatur og fremgangsmaate for pulsert administrering av vekstaktiverende midler.

Country Status (16)

Country Link
US (1) US4747825A (da)
EP (1) EP0190199A4 (da)
JP (1) JPS61502519A (da)
AU (1) AU4605385A (da)
BE (1) BE902783A (da)
BR (1) BR8506785A (da)
DK (1) DK294685A (da)
FI (1) FI852516L (da)
IL (1) IL75671A0 (da)
MW (1) MW686A1 (da)
NO (1) NO852603L (da)
OA (1) OA08214A (da)
PT (1) PT80738B (da)
RO (1) RO95012A (da)
WO (1) WO1986000233A1 (da)
ZA (1) ZA854916B (da)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089472A (en) * 1988-01-26 1992-02-18 Laboratorios Serono S.A. Use of growth hormone releasing factor for improving mental function
US5065748A (en) * 1989-11-14 1991-11-19 University Of South Florida Method of diagnosing growth hormone disorders employing somatostatin and growth hormone releasing hormone
US5065747A (en) * 1989-11-21 1991-11-19 University Of South Florida Method for improving the accuracy of diagnosis of growth hormone deficiency
US5428013A (en) * 1991-01-04 1995-06-27 Mugica; Jesus D. Differential diagnosis and treatment of the states of growth hormone insufficiency (or deficiency) with an alpha-2-adrenergic agonist and a growth hormone releasing peptide
US7910624B1 (en) 1995-03-03 2011-03-22 The Trustees Of Boston University Compositions for the treatment of blood disorders
WO1995011699A1 (en) * 1993-10-29 1995-05-04 The Trustees Of Boston University Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents
JPH10511095A (ja) * 1994-12-19 1998-10-27 ベス イスラエル ディーコネス メディカル センター インコーポレイテッド 副甲状腺ホルモン又はその作動薬の低用量継続投与
AU3889197A (en) 1996-07-26 1998-02-20 Douglas V Faller Compositions comprising an inducing agent and an anti-viral agent for the treat ment of blood, viral and cellular disorders
US6403647B1 (en) 1996-07-26 2002-06-11 Susan P. Perrine Pulsed administration of compositions for the treatment of blood disorders
US5939456A (en) * 1996-07-26 1999-08-17 Perrine; Susan P. Pulsed administration of compositions for the treatment of blood disorders
ES2146530B1 (es) * 1997-12-26 2001-04-16 Consejo Superior Investigacion Utilizacion del factor de crecimiento igf-i en la fabricacion de composiciones utiles en el tratamiento de la ataxia cerebelar.
WO1999040883A2 (en) * 1998-02-11 1999-08-19 Faller Douglas V Compositions and methods for the treatment of cystic fibrosis
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
WO2010105112A1 (en) * 2009-03-11 2010-09-16 Hemaquest Pharmaceuticals, Inc. Detection of short-chain fatty acids in biological samples
EP2459184A1 (en) 2009-07-31 2012-06-06 The Brigham and Women's Hospital, Inc. Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
US20110086869A1 (en) 2009-09-24 2011-04-14 The Trustees Of Boston University Methods for treating viral disorders
WO2011072086A1 (en) 2009-12-08 2011-06-16 Hemaquest Pharmaceuticals, Inc. Methods and low dose regimens for treating red blood cell disorders
WO2011113013A2 (en) 2010-03-11 2011-09-15 Hemaquest Pharmaceuticals, Inc. Methods and compositions for treating viral or virally-induced conditions
US9428565B2 (en) 2011-01-31 2016-08-30 The General Hospital Corporation Treatment and bioluminescent visualization using multimodal TRAIL molecules
US9585930B2 (en) 2011-03-20 2017-03-07 Trustees Of Boston University Therapeutic agent for emphysema and COPD
WO2012151474A2 (en) 2011-05-04 2012-11-08 Trustees Of Boston University Proton-motive force stimulation to potentiate aminoglycoside antibiotics against persistent bacteria
US20140227293A1 (en) 2011-06-30 2014-08-14 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
US20140271657A1 (en) 2011-10-12 2014-09-18 Children's Medical Center Corporation Combinatorial compositions and methods of treating hemoglobinopathies
WO2013071049A1 (en) 2011-11-10 2013-05-16 Trustees Of Boston College Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity
WO2013082275A1 (en) 2011-11-30 2013-06-06 Trustees Of Boston College Inhibitors of phosphodiesterases 11 (pde11) and methods of use to elevate cortisol production
WO2014022332A1 (en) 2012-07-31 2014-02-06 The Brigham And Women's Hospital, Inc. Modulation of the immune response
WO2014035474A1 (en) 2012-08-30 2014-03-06 The General Hospital Corporation Compositions and methods for treating cancer
HK1213788A1 (zh) 2012-10-12 2016-07-15 布里格姆及妇女医院股份有限公司 免疫應答的增强
WO2014130922A1 (en) 2013-02-25 2014-08-28 Trustees Of Boston University Compositions and methods for treating fungal infections
CA2924141C (en) 2013-08-22 2022-06-07 The General Hospital Corporation 5-amino 4-cyano substituted oxazole and thiazole derivatives as inhibitors of human 12/15-lipoxygenase
US11382883B2 (en) 2013-08-29 2022-07-12 Trustees Of Boston University Intermediate metabolism products to potentiate aminoglycoside antibiotics in bacterial infections
WO2015081073A2 (en) 2013-11-26 2015-06-04 The Brigham And Women's Hospital, Inc. Compositions and methods for modulating an immune response
ES2912283T3 (es) 2013-12-11 2022-05-25 Massachusetts Gen Hospital Uso de proteínas de tipo sustancia inhibidora mülleriana (SIM) para la anticoncepción y conservación de la reserva ovárica
EP3119913B1 (en) 2014-03-21 2021-01-06 The Brigham and Women's Hospital, Inc. Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
AU2015249946A1 (en) 2014-04-25 2016-11-17 The Brigham And Women's Hospital Inc. Methods to manipulate alpha-fetoprotein (AFP)
WO2015164605A1 (en) 2014-04-25 2015-10-29 The Brigham And Women's Hospital, Inc. Compositions and methods for treating subjects with immune-mediated diseases
EP3194446B1 (en) 2014-09-18 2022-10-26 Cedars-Sinai Medical Center Compositions and methods for treating fibrosis
CN116059378A (zh) 2014-12-10 2023-05-05 明尼苏达大学董事会 用于治疗疾病的遗传修饰的细胞、组织和器官
WO2016115345A1 (en) 2015-01-14 2016-07-21 The Brigham And Women's Hospital, Treatment of cancer with anti-lap monoclonal antibodies
US12551526B2 (en) 2015-04-22 2026-02-17 Cedars-Sinai Medical Center Enterically delivered bitter oligopeptides for the treatment for type 2 diabetes
EP3303286B1 (en) 2015-06-01 2023-10-04 Cedars-Sinai Medical Center Compounds that bind to rela of nf-kb for use in treating cancer
US20180185345A1 (en) 2015-06-19 2018-07-05 Trustees Of Boston University Methods and compositions for treating herpesvirus induced conditions
CN108349968A (zh) 2015-07-28 2018-07-31 维奥梅生物科学私人有限公司 抗菌治疗剂和预防剂
US10702586B2 (en) 2015-09-28 2020-07-07 Children's Hospital Los Angeles Methods for treating diseases mediated by ErbB4-positive pro-inflammatory macrophages
US12241053B2 (en) 2015-10-09 2025-03-04 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
JP7158104B2 (ja) 2016-07-15 2022-10-21 ビラクタ セラピューティクス，インク． Ｎｋ細胞ベースの療法で使用するためのｈｄａｃ阻害剤
US12447213B2 (en) 2016-10-07 2025-10-21 The Broad Institute, Inc. Modulation of novel immune checkpoint targets
JP2021513367A (ja) 2018-02-12 2021-05-27 ダイアベーツ−フリー， インコーポレイテッド 改善されたアンタゴニスト的抗ヒトｃｄ４０モノクローナル抗体
WO2020102454A1 (en) 2018-11-13 2020-05-22 Regents Of The University Of Minnesota Cd40 targeted peptides and uses thereof
AU2020283590A1 (en) 2019-05-31 2022-01-20 Viracta Subsidiary, Inc. Methods of treating virally associated cancers with histone deacetylase inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3498228A (en) * 1967-05-01 1970-03-03 Charles A Blumle Portable infusion pump
US3559644A (en) * 1967-12-14 1971-02-02 Robert F Shaw Liquid infusion apparatus
US3809871A (en) * 1972-12-01 1974-05-07 Nasa Programmable physiological infusion
US4273122A (en) * 1976-11-12 1981-06-16 Whitney Douglass G Self contained powered injection system
US4313439A (en) * 1980-03-24 1982-02-02 Biotek, Inc. Automated, spring-powered medicament infusion system
DE3015777A1 (de) * 1980-04-24 1981-10-29 Ferring Arzneimittel Gmbh, 2300 Kiel Vorrichtung zur intermittierenden pulsatorischen applikation von fluessigen arzneimitteln
US4306553A (en) * 1980-07-22 1981-12-22 The Regents Of The University Of Minnesota Method of maintaining the fluidity of hormone solutions for parenteral administration
US4517181A (en) * 1982-09-15 1985-05-14 The Salk Institute For Biological Studies Mammalian PGRF
US4529595A (en) * 1983-01-13 1985-07-16 The Salk Institute For Biological Studies GRF Analogs

Also Published As

Publication number Publication date
WO1986000233A1 (en) 1986-01-16
JPS61502519A (ja) 1986-11-06
FI852516A7 (fi) 1985-12-30
PT80738A (en) 1985-07-01
BR8506785A (pt) 1986-11-25
ZA854916B (en) 1986-02-26
US4747825A (en) 1988-05-31
IL75671A0 (en) 1985-10-31
FI852516L (fi) 1985-12-30
BE902783A (fr) 1985-10-16
PT80738B (en) 1986-12-11
AU4605385A (en) 1986-01-24
FI852516A0 (fi) 1985-06-26
EP0190199A1 (en) 1986-08-13
EP0190199A4 (en) 1987-12-01
DK294685A (da) 1985-12-30
DK294685D0 (da) 1985-06-28
MW686A1 (en) 1987-03-11
RO95012A (ro) 1988-09-15
OA08214A (en) 1987-10-30

Similar Documents

Publication Publication Date Title
NO852603L (no) Apparatur og fremgangsmaate for pulsert administrering av vekstaktiverende midler.
Ilson et al. Effect of a new synthetic hexapeptide to selectively stimulate growth hormone release in healthy human subjects
Bowers Growth hormone-releasing peptide (GHRP)
KR100200995B1 (ko) 골다공증 치료 또는 예방용 약제학적 조성물
AU624595B2 (en) Method for treating and preventing secondary effects of hyperinsulinemia and for treating type 2 diabetes, obesity and hyperlipidemia by application of insulin-like growth factor (IGF I)
Hirschberg et al. The delayed effect of growth hormone on renal function in humans
Skofitsch et al. Galanin and vasopressin coexist in the rat hypothalamo-neurohypophyseal system
VANCE et al. Lack of in vivo somatotroph desensitization or depletion after 14 days of continuous growth hormone (GH)-releasing hormone administration in normal men and a GH-deficient boy
REITER et al. The response of pituitary gonadotropes to a constant infusion of luteinizing hormone-releasing hormone (LHRH) in normal prepubertal and pubertal children and in children with abnormalities of sexual development
Kopelman et al. Growth hormone response to low dose intravenous injections of growth hormone releasing factor in obese and normal weight women
Hughes et al. The effects of simultaneous or separate infusions of some pro-opiomelanocortin-derived peptides (β-endorphin, melanocyte stimulating hormone, and corticotrophin-like intermediate polypeptide) and their acetylated derivatives upon sexual and ingestive behaviour of male rats
Walker et al. The role of neurotensin in human gallbladder motility
Smith et al. Nocturnal pulsatile growth hormone releasing hormone treatment in growth hormone deficiency
Walczewska et al. Estrogen and Leptin Have Differential Effects on Fsh and Lh Release in Female Rats (44441)
Riskind et al. Midbrain LHRH infusions enhance lordotic behavior in ovariectomized estrogen-primed rats independently of a hypothalamic responsiveness to LHRH
ARIMURA et al. Role of the neurohypophysis in the release of adrenocorticotrophic hormone in the rat
Word et al. The effect of gonadotropin-releasing hormone agonists on growth hormone secretion in adult premenopausal women
JP2866196B2 (ja) 不妊症治療用医薬
Ad Hoc Committee on Growth Hormone Usage, The Lawson Wilkins Pediatric Endocrine Society, and Committee on Drugs Growth hormone in the treatment of children with short stature
Guillemin Hypothalamic hormones: releasing and inhibiting factors
Del Pozo et al. Failure of oxytocin and lysine-vasopressin to stimulate prolactin release in humans
Frasier et al. Plasma growth hormone concentration after a single intramuscular injection of human growth hormone
Spark et al. Aldosterone production after suppression of corticotropic secretory activity
Cassorla et al. The effects of beta 1-adrenergic blockade on the growth response to growth hormone (GH)-releasing hormone therapy in GH-deficient children
Burger et al. Luteinizing hormone releasing factor in ultrafiltrates of blood collected from the pituitary stalk of ovariectomized rats and rats subjected to electrical stimulation of the preoptic area